The Best Source for Comprehensive Testing

The MORL is the best center in the United States to obtaining the full array of testing for thrombotic microangiopathies, streamlining a patient’s evaluation to a single institutional provider of these services.

Our Clinical Renal Diagnostics Division provides state-of-the-art next-generation sequencing (NGS) of all genes that have been implicated in hereditary thrombotic microangiopathies (TMAs) and C3G:

  • Complement-mediated TMAs
    • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Thrombotic Thrombocytopenic Purpura (TTP)
  • Metabolism-mediated TMAs
    • Cobalamin C Deficiency
    • DGKE TMA
    • G6PD Deficiency
  • C3 Glomerulopathy (C3G)
    • C3 Glomerulonephritis (C3GN)
    • Dense Deposit Disease (DDD)

The Clinical Renal Diagnostic Division of the MORL also performs a wide array of complement functional studies designed to aid healthcare providers in the diagnosis and treatment of this complex set of complement-mediated diseases:

  • Complement-mediated TMAs
    • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Thrombotic Thrombocytopenic Purpura (TTP)
  • C3 Glomerulopathy (C3G)
    • C3 Glomerulonephritis (C3GN)
    • Dense Deposit Disease (DDD)

Genetic Testing:

The Genetic Renal Panel simultaneously screens 12 genes (CFH, CFI, CD46 (MCP), CFB, CFHR5, C3, THBD, ADAMTS13, DGKE, MMACHC, PLG, and G6PD) known to be associated with the diseases listed above. The panel utilizes custom-targeted genomic enrichment and massively parallel sequencing to identify single nucleotide variants and small insertions/deletions. Multiplex Ligation-dependent Probe Amplification (MLPA) of the CFH-CFHR5 genomic region is additionally performed to identify large-scale deletions, duplications and complex rearrangements of this highly homologous region.

MLPA is available as a stand-alone test and is recommended for persons with C3G and aHUS.


Functional and Biomarker Testing:

Complement Functional testing provides important answers to many questions. Information can be provided on whether it is the right time for a transplant (whether a transplant might be successful avoiding a quick recurrence, i.e. kidney only or liver/kidney), and other adequate measures to consider. The MORL offers two large panels (C3G Functional Panel and TMA Functional Panel) to allow healthcare providers to get the "big picture" of their patient's current complement activity.  Providers can then follow several abnormal findings with our focused micro-panels; or follow a single level to monitor clinical treatments.

  • C3G Functional Panel provides serologies for C3GN and DDD patients.
  • TMA Functional Panel provides serologies for for aHUS and TTP patients.